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Abstract
Background: Lung metastasectomy in the treatment of advanced colorectal cancer has been widely adopted
without good evidence of survival or palliative benefit. We aimed to test its effectiveness in a randomised controlled
trial (RCT).
Methods: Multidisciplinary teams in 13 hospitals recruited participants with potentially resectable lung metastases to a
multicentre, two-arm RCT comparing active monitoring with or without metastasectomy. Other local or systemic
treatments were decided by the local team. Randomisation was remote and stratified by site with minimisation for age,
sex, primary cancer stage, interval since primary resection, prior liver involvement, the number of metastases, and
carcinoembryonic antigen level. The central Trial Management Group were blind to patient allocation until completion
of the analysis. Analysis was on intention to treat with a margin for non-inferiority of 10%.
Results: Between December 2010 and December 2016, 65 participants were randomised. Characteristics were well-
matched in the two arms and similar to those in reported studies: age 35 to 86 years (interquartile range (IQR) 60 to
74); primary resection IQR 16 to 35months previously; stage at resection T1, 2 or 3 in 3, 8 and 46; N1 or N2 in 31 and
26; unknown in 8. Lung metastases 1 to 5 (median 2); 16/65 had previous liver metastases; carcinoembryonic antigen
normal in 55/65. There were no other interventions in the first 6 months, no crossovers from control to treatment,
and no treatment-related deaths or major adverse events. The Hazard ratio for death within 5 years, comparing
metastasectomy with control, was 0.82 (95%CI 0.43, 1.56).
Conclusions: Because of poor and worsening recruitment, the study was stopped. The small number of participants
in the trial (N = 65) precludes a conclusive answer to the research question given the large overlap in the confidence
intervals in the proportions still alive at all time points. A widely held belief is that the 5-year absolute survival benefit
with metastasectomy is about 35%: 40% after metastasectomy compared to < 5% in controls. The estimated survival in
this study was 38% (23–62%) for metastasectomy patients and 29% (16–52%) in the well-matched controls. That is the
new and important finding of this RCT.
Trial registration: ClinicalTrials.gov, ID: NCT01106261. Registered on 19 April 2010
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Background
Standard care of colorectal cancer patients includes detec-
tion by active surveillance of asymptomatic metastases
followed by surgical resection in selected patients. Lung
metastasectomy is now regarded as ‘a pillar of modern
thoracic surgery’ [1] and is a substantial component of the
work of thoracic surgical units internationally. This activ-
ity has been reported increasingly in clinical case series
from the 1960s [2]. The publication of the International
Registry of Lung Metastases in 1997 established lung
metastasectomy in clinical practice [3]. The report con-
tains data on patients who had had a lung metastasectomy
performed by the contributing surgeons but, as is typical
in procedure-based clinical reporting, there were no com-
parable data on those who did not have metastases re-
moved. One small comparative study was published in
1980 [4]. It reported that the survival of 12 patients who
were potential candidates for metastasectomy but did not
have it was not dissimilar to 70 comparable patients who
had had lung metastasectomy. The number of metasta-
sectomy operations continued to increase during the
period 2000 to 2011 [5, 6] without any randomised trials,
a time when there were many controlled trials of systemic
therapies [7]. In 2013 a meta-analysis of the 25 largest
single-arm follow-up studies from 2000 to 2011, reported
an overall 5-year survival rate of 41% for patients having
lung metastasectomy for colorectal cancer, at an average
interval of about 2 years after primary resection. No con-
trolled studies were found and the authors concluded that
‘the benefit attributable to surgery is neither immediate
nor irrefutable’ [8].
There is some indirect evidence from controlled trials
that metastasectomy may not lengthen survival. There
have been two meta-analyses of randomised trials com-
paring more with less intensive surveillance in patients
treated for early colorectal cancer. Surveillance success-
fully advances detection: metastases were diagnosed up
to 2 years earlier. There were more surgical interven-
tions but there was no overall survival benefit [9, 10].
There was also uncertainty expressed by the authors of a
meta-analysis of colorectal cancer survival gains who
noted ‘that while indeed more metastasectomies are be-
ing performed, they have been made possible by better
therapies and that this benefit should be ascribed to the
therapies’ thus raising the possibility of reverse causation
[7]. That is to say that longer survival provides oppor-
tunities for more treatments rather than additional treat-
ments necessarily being the cause of longer survival.
Early expressions of doubt about the clinical effective-
ness of lung metastasectomy pointed to the lack of con-
trol data [4, 11] but the weight of current opinion is that
the observational evidence is sufficient [1]. However, the
proposed criteria set out for trusting clinical observation,
without the need for a controls, are not met [12]. The
effect of the intervention has to be mechanistically
plausible and a close temporal association between the
intervention and the desired outcome is required. The
variable course of cancer, and the deliberate selection of
patients with very few metastases and a slower course,
makes picking the signal from the noise impossible [12].
The missing evidence is control data on the survival of
patients with features making them eligible for, but who
did not actually have, metastasectomy. The need for this
evidence led to the Pulmonary Metastasectomy in Colo-
rectal Cancer (PulMiCC) randomised controlled trial
which we report here.
Methods
Study design
PulMiCC was a two-stage, randomised, Phase-III, parallel-
arm, multicentre trial.
The setting was hospital-based multidisciplinary teams
(MDTs) managing patients with advanced colorectal
cancer. The principal investigator (PI) at each trial site
was a medical member of the team, either a surgeon or
an oncologist. The study was set up in 24 hospitals treat-
ing advanced colorectal cancer: 21 were in Britain, with
one each in Serbia, Italy and China.
The trial was co-ordinated from October 2009 to March
2014 by the Clinical Trials and Evaluation Unit, Royal
Brompton and Harefield NHS Foundation Trust, London.
PulMiCC administration and trial management then
moved to the Surgical and Interventional Trials Unit
(SITU), University College London. Both units are subse-
quently referred to as ‘the Trials Unit’. The co-ordination
of patient-reported outcomes (PROs) throughout was at
Sussex Health Outcomes Research and Education in Can-
cer (SHORE-C), University of Sussex.
Ethics approval and consent to participate
Central ethical approval was confirmed from the Na-
tional Research Ethics Committee London – Hampstead
(ref approval no. 10/H0720/5) and did not begin recruit-
ing at other centres in the trial until local ethical ap-
proval was obtained. Written informed consent was
obtained at enrolment (Stage 1) and separately at ran-
domisation (Stage 2).
The trial protocol can be accessed on line.
https://www.ucl.ac.uk/clinical-operational-research-
unit/sites/clinical-operational-research-unit/files/pulmicc_
protocol_december_2015.pdf
A description of the trial can be accessed on line.
https://clinicaltrials.gov/ct2/show/study/NCT01106261
?show_desc=Y#desc
Patient participants
Eligible for inclusion were adults who had undergone re-
section of primary colorectal cancer with a prospect of
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cure, but who now had pulmonary metastasis, con-
firmed on routine review. In participating centres all
such patients were reviewed by a properly constituted
multidisciplinary team (MDT) responsible for all man-
agement decisions, advice and support of patients.
Previously treated liver metastases were allowed but
there had to be no other metastatic site. There had
to be no clinical indication of active colorectal cancer,
by investigations including imaging by computerised
tomography (CT) and positron emission tomography
(PET). Exclusion criteria were previous malignancy,
concurrent illness, or unavailability for follow-up that
was likely to interfere with treatment per protocol or
the measurement of endpoints, or if mental incapacity
precluded fully informed consent.
Biopsy proof was preferred but if, based on the above
investigations, there was 90% clinical confidence that the
diagnosis was of colorectal metastasis that was accepted.
Patient participants were recruited from the MDT
meetings, invited to participate and registered for evalu-
ation in Stage 1 after written informed consent. Those
subsequently eligible for randomisation and for whom
the MDT was in equipoise about the benefit of metasta-
sectomy, were offered random assignment to have
metastasectomy or not, after receiving a full explanation
and giving written consent (Stage 2). All participants
had continued active monitoring.
Trial process: a designated clinical team member in-
formed potentially eligible patients of the MDT find-
ings and explained the trial, emphasising the
uncertainty of the evidence for the management of
pulmonary metastases. Those interested in participat-
ing were given a patient information leaflet and an
explanatory Digital Video Disc (DVD) to take home.
A healthcare professional training DVD was also
available for clinicians to aid their discussions with
patients. The trial was administered by clinical trials
staff at the local hospital site under the direction of
the PI. Medical MDT members provided information
and dates of events and measurements appropriate to
their specialty. These were collated locally and
returned to the Trials Unit on Clinical Report Forms
(CRFs). Once a patient consented to join Stage 1,
registration was carried out by the Trials Unit.
Following evaluation and any systemic treatments con-
sidered appropriate, eligible patients were approached by
the oncologist or other designated member of the clin-
ical team and asked if they were willing to consider the
second (randomised) stage of the trial. All patients eli-
gible for Stage 2 of the trial, whether or not they had
chosen to proceed to randomisation, were invited to
complete a questionnaire exploring their reasons for
accepting or declining trials; this was completed at home
and returned by post to SHORE-C [13].
Patients who confirmed their willingness to be rando-
mised were asked to sign a second consent form and
complete a set of baseline questionnaires: Functional As-
sessment of Cancer Therapy – General and Anaemia
sub-scale (FACT-G-An) [14] plus selected items from
the six-item Lung Cancer Brief Symptom Index [15] and
the six-item short form of the Spielberger State/Trait
Anxiety Inventory (STAI) [16]. The EQ-5D-3L (Euro-
QoL 5-Dimension 3-Level) questionnaire was adminis-
tered for health economic evaluation [17].
Randomisation and masking
Random assignment was to active monitoring (Control)
or the same plus metastasectomy (Metastasectomy).
Randomisation was stratified by local site. Patients were
allocated equally between the treatment arms. Sequence
generation was at www.sealedenvelope.co.uk using a mini-
misation programme incorporating the participant’s age,
sex, T(umour) stage, N(odal) stage, prior liver metastasect-
omy, time since resection of the colorectal primary cancer,
number of metastases, and carcinoembryonic antigen
(CEA) level. A random element was included such that
each patient retained a non-zero probability of being ran-
domised to each of the treatment arms. The trials staff
transmitted the request and received the allocation elec-
tronically. Because the allocation was performed remotely,
the process was completely concealed from the investiga-
tors and the Trials Unit.
Because the management options were so different
(operation or no operation) blinding of participants and
the site staff was not possible. The Trial Management
Group (TMG) remained completely blind to allocation
until after the primary analysis was done and the trial
statistician and the TMG agreed the release of the full
database for further analysis.
Procedures
Control participants were to be managed without metas-
tasectomy, radiotherapy or image-guided thermal abla-
tion (IGTA). If these treatments were used subsequently,
the patient remained in the assigned arm for follow-up
at the specified time points from randomisation on the
intention-to-treat principle.
Participants assigned to lung metastasectomy were to
undergo surgery with the objective of an R0 resection
(that is, histologically confirmed clear margins). The sur-
gical approach (videothoracoscopy or open thoracotomy)
was at the discretion of the surgeon.
Patients were seen for clinical examination including
performance status, weight, lung function, CEA (carci-
noembryonic antigen) assay and CT at 3, 6, 9, 12, 18, 24,
36, 48 and 60months.
Treasure et al. Trials          (2019) 20:718 Page 3 of 13
Outcomes
The primary outcome was overall survival from the date
of randomisation, with all patients being followed until
the date of censoring or 60 months, whichever was
shorter. Any surgery, radiotherapy, ablations or chemo-
therapy since the last report were recorded. In the event
of crossovers a secondary analysis by treatment received
was to be carried out.
Secondary endpoints were changes in lung function
(forced expiratory volume in the first second (FEV1) and
percentage predicted FEV1) and, over the period of 24
months following randomisation, patient-reported anx-
iety and quality of life.
The primary patient-reported outcome measure was
the Functional Assessment of Cancer Therapy –An-
aemia and Lung sub-scales (FACT An-L) Trial Outcome
Index (TOI), which comprises the sum of scores from
37 items included in the FACT-G physical (seven items)
and functional (seven items) well-being sub-scales to-
gether with the anaemia sub-scale (20 items) and three
Fig. 1 a The PulMiCC trial profile. b Sankey diagram of the PulMiCC trial flow through Stage 1, Stage 2, assignment and treatment
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items from the Functional (Lung) Symptom Index Score
(FLSI), not represented elsewhere in the FACT-G-An
questionnaire [18–20].
Statistical analysis
Sample size: a 10% difference in overall mortality at 3
years was taken to be the minimally important clinical
difference (MID) and the inferiority margin for the de-
sign of the PulMiCC non-inferiority trial. Under the as-
sumption of exponential survival curves, and with an
expected 3-year survival rate of 30% in the interventional
arm of the trial, then a 20% survival rate for the non-
interventional arm would correspond to a relative risk of
death for the non- interventional vs the interventional
patients of 1.3. A sample size of 1350 registered patients
was estimated to provide 1:1 randomisation of 300 pa-
tients. This was felt to be a practical sample size al-
though it was hoped that perhaps as many as 150
additional patients could be randomised. Under the
given survival assumptions, based on estimation of the
log relative risk and the assumption that 72 patients
from the pilot/feasibility study would be included with
subsequent patients entering the trail uniformly over a
3-year period, simulations and asymptotic power calcula-
tions both indicated that a sample size of 300 would
provide 78% power to detect an increased relative risk of
death of 1.3 for patients in the non- interventional arm,
when testing at the one-sided 5% level and this was
adopted as the desired sample size in the trial protocol
on this basis. This corresponds to a standard error of es-
timation for a 10% survival difference of 4.2%.
Comparative analysis: for the primary outcome of sur-
vival, Kaplan-Meier estimates of survival curves were
produced. Treatment arms were compared through
fitting a Cox relative-risk regression model [21], with an
assumption of proportional hazards, which provided es-
timated hazard ratios and confidence intervals (CIs). The
primary analysis was adjusted for minimisation variables.
For the as-treated analysis, comparison was based on a
time-dependent binary explanatory variable reflecting
the time at which a metastasectomy occurred.
For lung function (FEV1 and predicted % FEV1) we
used linear regression models with estimation using gen-
eralised estimating equations (GEE) to adjust for within-
patient correlation. The primary analysis was to estimate
a common effect of metastasectomy over time, with ad-
justment for follow-up time and baseline measurements,
but variation in the treatment effect over time was ex-
amined. The potential impact of losses to follow-up was
examined through fitting singular linear increment
models [22]. Comparable linear model methods were
used for patient-reported outcome data.
To reflect the high correlation between baseline and
subsequent measures for all patient-reported outcomes
(PROs) other than the STAI (anxiety), we used the
change in scores from baseline at 3, 6, 12 and 24
months. For all outcomes, models which included base-
line score were fitted to examine the appropriateness of
differencing. Estimated differences between the treat-
ment arms and associated 95% CIs were calculated and,
where appropriate, compared with minimally important
differences (MIDs). The null hypotheses addressed were
of no differences in quality of life expected between
Metastasectomy and Control. There was a particular
focus on the alternatives that patients who are rando-
mised to surgery would experience more lung function
symptoms and that patients who are not randomised to
surgery would experience greater anxiety.
Table 1 Principle Investigators, Centre and the number of randomised
Principle investigator Clinical centre Randomisations
John Edwards Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield 18
David Tsang Basildon and Thurrock University Hospitals NHS Foundation Trust, Basildon 8
Joel Dunning The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough 7
Mike Shackcloth Liverpool Heart And Chest Hospital NHS Foundation Trust, Liverpool 7
Tim Batchelor Bristol Royal Infirmary, University Hospitals Bristol NHS Foundation Trust, Bristol 5
Aman Coonar Royal Papworth Hospital NHS Foundation Trust, Cambridge 5
Jurjees Hasan The Christie NHS Foundation Trust, Manchester 4
Brian Davidson Royal Free London NHS Foundation Trust, London 3
Adrian Marchbank Derriford Hospital, University Hospitals Plymouth NHS Trust, Plymouth 2
Simon Grumett New Cross Hospital, The Royal Wolverhampton NHS Trust, Wolverhampton 2
Eric Lim Royal Brompton Hospital, Royal Brompton and Harefield NHS Foundation Trust, London 2
Apostolos Nakas Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester 1
Stelios Vakis Queen’s Hospital, University Hospitals of Derby and Burton NHS Foundation Trust, Burton upon Trent 1
Total randomised 65
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Results
The first randomisation was on 2 December 2010 and
the last on 24 November 2016. Recruitment slowed from
2015 and never recovered. We closed the trial in Decem-
ber 2016. At that time there were 512 of an intended
1350 registrations in Stage 1 and, of 300 patients re-
quired by the power calculation, we had randomised 93
(Fig. 1). The centre in Vojvodina, Serbia failed to return
their CRFs because of unresolvable problems with trial
support. We had only baseline data on two randomised
patients, one in each group. After several discussions
with the Independent Data Monitoring Committee
(IDMC) we decided to exclude the site. Remaining from
13 sites, were 65 randomised participants, 33 in the
Control arm and 32 assigned to Metastasectomy
(Table 1). Apart from the excluded site in Serbia, no
other patients have been lost from follow-up for the pri-
mary outcome which is survival. Ten sites registered pa-
tients but did not randomise any. The prospectively
collected data on the full cohort of 512 patients and
their survival will be analysed and reported separately as
an observational study.
Minimisation produced balanced groups and limited
the potential for unexpected confounding (Table 2).
Figure 2 presents estimated survival curves for the
Metastasectomy and Control arms. There were 21
deaths in the Control arm and 17 in the surgical arm.
The estimated hazard ratio comparing the relative sur-
vival rates in the Metastasectomy versus the Control
treatment arm, adjusting for and, therefore, comparing
patients with comparable minimisation variables, was
0.69 with a 95%CI of (0.35,1.37). The unadjusted esti-
mated hazard ratio was 0.82, 95%CI (0.43, 1.56) and un-
adjusted non-parametric median estimates, in years,
were 3.91, 95%CI (2.99,∞), and 3.38, 95%CI (3.11,∞), for
the Metastasectomy and Control arms, respectively.
Overall estimated survival at 4 years for the Control
group was 40% (95%CI 26–63%) and 43% (95%CI 27–
66%) for those assigned to metastasectomy. At 5 years,
estimated survival was 29% (16–52%) and 38% (23–62%)
for the Control and Metastasectomy arms. The 5-year
gap (in estimated survival) emerges as there were 3/11
deaths in the Control arm in year 5 and 1/9 in surgery.
For the ‘as treated’ analyses, two patients assigned to
metastasectomy did not undergo surgery, both of whom
died. No patient in the Control group had crossed over
to metastasectomy at the 3-month evaluation point and
there was only one thereafter, 27 months after random-
isation. The comparable adjusted and unadjusted esti-
mated hazard ratios for these analyses were 0.60, 95%CI
(0.30, 1.22) and 0.78, 95%CI (0.41, 1.50). Two patients
turned out to not have colorectal lung metastases, one
in each arm. The patient in the surgical arm had two
intrapulmonary lymph nodes resected. The patient in
the Control arm had three lung opacities which were
not biopsied and disappeared spontaneously over subse-
quent months. They remain in the analysis based on
intention-to-treat.
At 5-year follow-up FEV1-related measurements were
only available for three patients in the Metastasectomy
arm and one in the Control arm. This precludes inform-
ative analysis at this time point and treatment compari-
sons were, therefore, restricted to time points up to 48
months. Based only on observed patients, for FEV1 there
is no evidence of an effect with an estimated average dif-
ference over time, based on GEE and adjusted for base-
line and follow-up time, of − 0.05, 95%CI (− 0.21, 0.12).
Table 2 Variables used for minimisation. The process achieved
well balanced groups
Control (N = 33) Metastasectomy (N = 32)
Male 20 21
Female 13 11
Age Years Years
Minimum 48 35
25% 61 61
Median 70 72
75% 76 74
Maximum 86 83
CRC T Stage
T1 1 2
T2 4 4
T3 23 23
Missing 5 3
Total 33 32
CRC N Stage
N1 15 16
N2 13 13
Missing 5 3
Prior liver resection
Yes 9 8
No 24 24
CRC interval Months Months
Minimum 7.6 1.0
25% 17.4 13.9
Median 26.4 22.0
75% 34.8 36.8
Maximum 130.5 106.5
Lung metastases
1 14 14
2 to 4 18 16
5 + 1 2
CRC colorectal cancer, N nodes, T tumour
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For percentage predicted FEV1, there is an estimated
overall effect associated with metastasectomy of − 4.93,
95%CI (− 10.57, 0.70). The correlations of subsequent
lung function measures with baseline are 0.855 and 0.75
for FEV1 and percentage predicted FEV1, respectively.
Figures 3 and 4 present estimates of the mean FEV1
and percentage predicted FEV1, respectively, in the two
treatment arms at various follow-up times, with a com-
mon baseline starting value assumed in both arms corre-
sponding to the average baseline in all patients. The
means are connected by straight lines for presentation
purposes only. Estimates based on singular linear models
that illustrate the possible effect of drop-out are pre-
sented here. It can be seen that the apparent observed
increase in FEV1 and percentage predicted FEV1 values
at later follow-up times may be importantly influenced
by drop-out. For both sets of estimates, there is an ap-
parent cross-over of the values with the metastasectomy
patients having lower values in the first year or so but
showing an increase thereafter. Formal 1 df tests, based
on GEE estimation, for variation in the arm effect over
(linear) time generated p values of 0.11 and 0.02 for
FEV1 and % predicted FEV1, respectively.
There were no treatment-related deaths or major ad-
verse events.
A total of 21 of 65 patients were reported by CRF as
treated with chemotherapy over the course of the 5 years
with no significant difference in numbers between the
two arms: Control 9/33; Metastasectomy 12/32. Some
patients had received repeated treatments. Chemother-
apy within 6 months of randomisation was given in five
patients in each arm.
A total of 11 patients had had radiotherapy in the 5-
year follow up period, 6/33 in the Control group and 5/
32 in the Metastasectomy groups, none of which were
within 6 months of randomisation and were dispersed
without a pattern thereafter. In at least one instance in
each group the reported radiotherapy was to treat me-
tastases elsewhere (brain and bone). Two patients in
each group were treated with radiofrequency ablation.
No treatments were in the first 6 months after
randomisation.
All but one patient had an ECOG (Eastern Coopera-
tive Oncology Group) performance score of 0 or 1 at
baseline. There is no suggestion of a difference between
the arms.
Figure 5 presents the mean patient-reported outcome
scores over the 24months of follow-up. For no outcome
was a significant effect of metastasectomy detectable.
For example, for the change in TOI from baseline, the
Fig. 2 Kaplan-Meier analysis with 95% confidence intervals
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estimated effect was − 1.51, 95%CI (−.90, 4.88). An early
drop in the FLSI score (that is lung symptoms) for pa-
tients receiving surgery is observed as expected. While
drop-out is significant, particularly at 24 months, lin-
ear increment analyses do not generate any qualitative
difference for these outcomes. Minimal important dif-
ferences for TOI, FACT-G, FACT-An-20 and FLSI,
taken from the literature are 7.66, 5–7, 4.57 and 1.30,
respectively. Such differences lie outside of, or
towards the limit of the 95% CIs for the estimated ef-
fects for these four outcomes, on the change from
baseline scale, which were (− 7.90,4.88), (− 5.77,3.02),
(− 3.94, 4,45) and (− 1.56,0.56), respectively.
Variations in patients’ weights in the two arms of the
trial was dominated by reducing numbers and widening
standard deviation. There was no discernible difference
between trial arms.
Exploratory analysis of the reasons for not randomising
The three most active centres (Sheffield, Liverpool and
Bristol) were asked to provide reasons why patients con-
senting into Stage 1 of PulMiCC were not randomised.
Of this subset of 155 patients, fully informed during the
period of assessment, 41 made their own decision. The
split to undergo or not undergo metastasectomy was 22:
19. However, when the clinicians made the decision 99%
(77/78) had metastasectomy. Ten patients had other
pathology (nine lung cancer; one carcinoid). No con-
straint on the number of metastases was in the protocol
but one unit set its own limits at two to four – deeming
patients outside this range not eligible for randomisa-
tion. Of 18 patients deemed ineligible, half of the reasons
were not aligned with the written protocol. At trial clos-
ure, of the 512 patients in Stage 1, 82% were not rando-
mised resulting in an inconclusive result. Fig. 6 shows
the Sankey diagram for reasons for non-randomisation.
Discussion
Because of recruitment difficulties PulMiCC closed early
and we were unable to reach the desired statistical end-
points and convincingly answer the question about the
value of pulmonary metastasectomy. In the subset of
155 patients whose reasons for non-randomisation were
examined, at least 56% were lost to randomisation by cli-
nicians’ decisions. The 41 patients who decided for
themselves whether or not to undergo metastasectomy
did so in numbers which better reflected equipoise.
Fig. 3 Estimated mean forced expiratory volume in the first second (FEV1) values in the two treatment arms with a common baseline starting
value assumed in both arms corresponding to the average baseline in all patients. Dashed lines based on generalised estimating equations and
solid lines based on singular linear models that adjust for drop-out. The 95% confidence intervals are provided for the singular linear model fits
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Nevertheless, we believe that the results in 65 rando-
mised patients have some important implications.
The survival of patients undergoing metastasectomy
in PulMiCC was similar to that found in a quantita-
tive synthesis of all follow-up studies up to 2007 [23]
and the meta-analysis of larger observational studies
up to 2011 [8]. Five-year survival was around 40% in
all three. The PulMiCC 5-year survival (38% (23–
62%)), therefore, appears to be a valid reflection of so
called ‘real world’ practice. But survival of the Pul-
MiCC Control patients was better than is generally
assumed (29% (16–52%)) for those with untreated
colorectal lung metastases. Because of small numbers,
the confidence limits are wide but the difference be-
tween the survival of those undergoing metastasect-
omy and that of the untreated patients with
colorectal lung metastases is likely to be smaller than
is currently assumed. PulMiCC is the only rando-
mised trial of colorectal cancer metastasectomy. Be-
cause the point estimate of the HR was 0.82, our
findings are compatible with the belief that some pa-
tients, in whom lung metastases are truly the only
residue of their colorectal cancer, may survive long
term as a direct result of metastasectomy. But they
call into question the belief that there is a very low
likelihood of 5-year survival without metastasectomy
in comparable patients.
Lung metastases generally remain asymptomatic and
rarely contribute to terminal events and so there is un-
likely to be significant palliative benefit from metasta-
sectomy. There was a reduction in quality of life (QoL)
at 3 months in those assigned to operation as would be
expected among patients undergoing surgery (Fig. 5) and
there was a detrimental effect on lung function from 3
months to 1–2 years after pulmonary resection com-
pared with Control (Figs. 3 and 4). Neither difference
was sustained or significant in the longer term, but the
already small numbers of patients available for assess-
ment declined by 3 years to fewer than 20 in each arm,
most with ongoing cancer, making data uninterpretable.
Although ‘psychological benefit’ is given as a justification
for metastasectomy, we found no difference in anxiety
between the two arms. Individual patients may have felt
relieved to be rid of the radiologically visible vestiges of
their cancer, but reduced anxiety was not seen as a
group effect in this controlled trial. The lack of differ-
ence also indicates that informed patients can come to
terms with the presence of lung metastases. This is in
Fig. 4 Estimated mean percentage predicted forced expiratory volume in the first second (FEV1) values in the two treatment arms with a common
baseline starting value assumed in both arms corresponding to the average baseline in all patients. Dashed lines based on generalised estimating
equations and solid lines based on singular linear models that adjust for drop-out. Confidence intervals are provided for the singular linear model fits
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line with the only one late crossover from the Control to
the Metastasectomy arm of the trial.
Comparative ‘before and after’ data on pulmonary
function were not given in any of observational studies
[2] which is consistent with the under-reporting of
harms that has been found to be a feature of cancer tri-
als [24]. The overriding limitation of this study is its
small size with only 65 participants. This was, in large,
part due to the difficulty clinicians had in presenting
uncertainty to patients who were referred to them in the
hope of cure [25]. It was also clear that the default of
MDTs was to offer intervention rather than randomisa-
tion with a chance of assignment to a Non-
metastasectomy arm. As a result of the subset analysis of
155 patients from the three most recruiting centres we
think that this bias resulted in loss to randomisation of
the majority of all patients who had consented to be in a
randomised trial.
There are many well-documented instances where
there has been a reversal from a prior standard of care
Fig. 5 Patient-reported outcomes comparing the two arms of the trial. TOI Trial Outcome Index. FACT-AnL Functional Assessment of Cancer Therapy.
FACT-G Functional Assessment of Cancer Therapy. General. FACT-An-20 Functional Assessment of Cancer Therapy – Anaemia sub-scale. STAI Spielberger
State/Trait Anxiety Inventory. FLSI Lung Cancer Brief Symptom Index
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after the fair test of a randomised controlled trial (RCT)
[26, 27]. There are important precedents for finding that
when subjected to a controlled trial, more radical sur-
gery has not resulted in better cancer outcomes [28, 29].
Randomised trials of interventions, and particularly sur-
gery versus no active treatment, are difficult to conduct
and so tend to be relatively small but do provide a much
more reliable estimate of differences between treatments
than uncontrolled observations. More contentious are
small trials which find no difference, such as the analysis
of pooled trial data on 58 patients, which suggested that
stereotactic radiotherapy might be have similar out-
comes to lobectomy in the treatment of primary lung
cancer [30]. PulMiCC is open to the same criticism of
being small and, therefore, underpowered but if lung
metastasectomy for colorectal cancer was not already in
practice, it would not be possible to propose its intro-
duction in the light of these findings. Although not
proving an absence of any survival difference, a duty of
candour should include sharing with patients that there
might be no benefit from metastasectomy. That alone
would help in recruiting to any future trials and improve
evidence for clinical practice.
The difficulty faced by clinicians in declaring uncer-
tainty is real and well recognised [31–35]. A trial which
has been deemed ethically and scientifically sound
should be presented to patients in a neutral and inform-
ative fashion by an individual trained and trusted to do
this job. Clinical consultation is then about explaining
the assigned treatment and about building trust and
confidence. If the reverse occurs and the trial is first
introduced by a clinical practitioner, it may be difficult
to convey a sense of uncertainty and equipoise. In best
clinical cancer practice the multidisciplinary team
weighs up the options and then consultation is arranged
with the appropriate treating clinician. In PulMiCC there
was a clear exercise of bias with the MDTs overriding
equipoise. This resulted in the exclusion of many pa-
tients who had given their informed consent. Learning
from this and similar experiences, later UK trials of thor-
acic oncology (MARS-2, VIOLET) have recruited well
after specific training in the QuinteT method for ran-
domisation into surgical trials [35]. PulMiCC provides
an example of the difficulties of running a randomised
trial that challenges established clinical practice even
when this is based on insecure observational evidence. It
is easier to implement an intervention in the manage-
ment of cancer, in the absence of evidence, than to seek
the evidence that might demonstrate its futility.
The belief in metastasectomy is firmly entrenched;
oligometastatic disease is now abbreviated to OMD
[36–38]. The debate has moved on: it is not whether
to treat, but how to treat. Should it be with surgery
or IGTA including radiofrequency ablation and cryo-
ablation? The current drive is towards stereotactic
(ablative) body radiotherapy (abbreviated as SABR/
SBRT) for metastases [39]. There has already been
large investment; practitioners, for-profit health pro-
viders and the devices industry all expect a return on
this investment [40]. However, it is probably more
rational to treat systemic cancer with the now more
effective systemic treatments [7].
Fig. 6 Sankey diagram of reasons for not randomising
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In colorectal cancer the evidence from a meta-analysis
of 16 RCTs showed no survival benefit from detecting
metastases 1–2 years earlier, indicating that the growing
practice of metastasectomy may not improve survival.
These findings were regarded as ‘bleak nihilism’ by the
British Journal of Surgery’s editor who wrote: ‘it is coun-
terintuitive that earlier identification of metastatic dis-
ease does not improve survival’ [10]. The findings were
confirmed by a Cochrane review [9]. The accumulated
evidence from 16 RCTs is, for us, more persuasive than
intuition. The retreat from radical mastectomy as the
standard of care for breast cancer took many years of
erosion of the intuition which pursued the belief that the
bigger the operation the better [41]. Trials proved that it
was time to call a halt to unavailing mutilation [28, 42].
The findings of PulMiCC should at least raise enough
doubt for health services to call for better evidence, and
it will require a larger number of randomised patients to
show whether or not metastasectomy improves survival
and, if so, by how much and for which patients. Five
hundred and twelve patients consented to participate in
the PulMiCC trial. Any future trial would have a power
calculation informed by PulMiCC data but the imple-
mentation of the protocol would need to overcome the
bias clearly exercised resulting failure to randomise such
a high proportion of participants. Better training by
methods such as QuinteT should be employed but it
would also be important for clinicians with a vested
interest in delivering particular treatments, including
surgery, radiotherapy and other ablative techniques, to
not be able to subvert the process of unbiased assign-
ment, for reasons set out above [25]. In the light of the
PulMiCC findings it seems improbable that the effect of
excision or ablation of lung metastases can be as great as
is believed at present.
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